Committed to developing novel vaccines against major infectious diseases and public health threats worldwide
Patronus Biotech, the Group's vaccine division, is China’s first vaccine enterprise focused on the Universal Virus-like Particle (U-VLP®) technology platform. This technology overcomes the limitations of traditional VLP approaches regarding pathogen types, as well as technical bottlenecks in production capacity and stability. Multiple invention patents have been granted. The company has established pilot and commercial-scale production facilities that meet international standards, with an annual production capacity of up to 10 billion doses. Leveraging the U-VLP® technology platform, the company has developed a pipeline addressing clinically urgent needs, including vaccines for shingles, RSV, respiratory combination vaccines, tuberculosis, and malaria. Among these, the shingles and RSV vaccines have completed Phase II clinical trial enrollment, while other candidates have achieved breakthrough progress in preclinical studies and are advancing toward IND applications.
Unique U-VLP™ (Universal Virus-Like Particles) platform
Breaks through the limitations of traditional VLP technology in pathogen types
Stable and high yield:
Breaks bottlenecks of traditional VLP manufacturing technology
Broad spectrum:
Can be used for rapid development of a wide range of pathogenic vaccines, including emergency products such as COVID vaccine
Stronger efficacy:
Particle presentation improves the immunogenicity of otherwise poorly immunogenic protein antigens, together with steric presentation promotes conserved epitopes recognition thus higher broadly neutralising antibody titers
Pilot workshop
Manufacture workshop
TOP